Bradmer Pharmaceuticals

Bradmer extends patent portfolio with allowance letter from European Patent Office

Published in Law and Health Weekly, July 8th, 2006

Bradmer Pharmaceuticals, Inc., a biotechnology company dedicated to the development and commercialization of cancer therapies, announced that the European Patent Office has issued a letter of allowance for a patent titled "Radioconjugation of Internalizing Antibodies" to the company's license partner Duke University.

The patent relates to the composition of antibody conjugate materials and the methods to enhance and preserve the attachment of radioactive molecules to therapeutic antibodies that are taken into certain diseased cells and subsequently kill them. A corresponding patent with a similar description was issued by the U.S. Patent and Trademark Office, as U.S....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Law and Health Weekly

Source: Law and Health Weekly (2006-07-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry